DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Effect of Parathyroid Hormone (PTH) and Weight-Bearing on Bone in Spinal Cord Injury (SCI)

Information source: Northwestern University
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Osteoporosis; Bone Loss; Spinal Cord Injury

Intervention: teriparatide (Drug); weight-bearing (Other)

Phase: Phase 4

Status: Completed

Sponsored by: Thomas J. Schnitzer

Official(s) and/or principal investigator(s):
Thomas J Schnitzer, MD, PhD, Principal Investigator, Affiliation: Northwestern University


Individuals with spinal cord injury sustain significant loss of bone mass in their lower extremities (20-40% or more). This study evaluates the ability of PTH and weight-bearing, two interventions that build bone, to increase bone mass in this population.

Clinical Details

Official title: Effect of PTH Combined With Weight-Bearing on Bone Density and Bone Architecture in People With Spinal Cord Injury

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: BMD at Left Total Hip

Secondary outcome: P1NP

Detailed description: This pilot project aims to evaluate PTH with weight-bearing in a group of individuals with chronic SCI and loss of bone mass in their lower extremities. A convenience sample of 12 people with SCI will be enrolled into a 6 month study assessing the effects of a weight-bearing regime plus daily PTH (Forteo 20ug sc) on BMD and bone markers. Subjects will be evaluated at 3 and 6 months after initiating treatment with measurement of bone density as well as bone markers of formation and resorption. An optional extension to 12 months will be offered to all subjects.


Minimum age: 18 Years. Maximum age: 75 Years. Gender(s): Both.


Inclusion Criteria: 1. Age 18-75 years

2. Complete SCI - total loss of motor function below level of lesion

3. Capable of positioning to have DEXA performed 4. Capable of undertaking the weight-bearing exercise regime 5. Capable of reading and understanding informed consent document 6. Able to self-administer PTH or have someone in the family who can do so 7. T score <-2. 5 or Z score <-1. 5 on evaluation of total hip BMD 8. No known endocrinopathies 9. Normal TSH levels 10. Normal 25-OH vitamin D levels 11. Normal calcium levels 12. Normal renal function (creatinine <2. 0mg/dl) 13. Able to return for all follow-up visits Exclusion Criteria: 1. Surgical or other intervention resulting in metal or anatomy precluding obtaining DEXA and/or MRI measurements 2. Other medical conditions that in the opinion of the investigator would preclude the subject from completing the study 3. History of malignancy 4. History of radiation therapy 5. Unable to self-administer PTH or have it administered 6. Elevated liver function tests >2x normal 7. For males, significantly abnormal free testosterone levels 8. Currently being prescribed anti-convulsants 9. Currently being prescribed glucocorticoids, other than inhaled glucocorticoids 10. Currently being prescribed any bone-active agents, including any bisphosphonate, raloxifene, hormone therapy (estrogen and estrogen/progestin), calcitonin or strontium-containing compounds. 11. No previous history of bisphosphonate use 12. No previous use of other bone-specific agents during past 2 years

Locations and Contacts

Rehabilitation Institute of Chicago, Chicago, Illinois 60611, United States
Additional Information

Starting date: June 2009
Last updated: June 3, 2013

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017